Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Polycystic Ovary Syndrome 3Infertility 1Anovulation 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Glycoprotein Hormones, alpha Subunit × Clear all
NCT01653743 2016-01-07

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
81 enrolled 11 charts

Anovulation, Polycystic Ovary Syndrome

NCT01081626 2014-02-13

Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

Merck KGaA, Darmstadt, Germany

Phase 4 Completed
310 enrolled 18 charts

Infertility, Polycystic Ovary Syndrome

NCT01185704 2014-02-13

ATTAC-PCO

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
136 enrolled 21 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡